Vyriad, Imanis Ink Cancer Companion Dx Development Deal

Aug 16, 2016

|

NEW YORK (GenomeWeb) – Vyriad announced today that it has partnered with Imanis Life Sciences to develop in vitro and in vivo tests to predict a patient's likelihood of responding to its oncolytic virus therapeutics.

Vyriad is developing cancer treatments that use vesicular stomatitis and measles viruses modified with genes encoding known tumor antigens in order to trigger anticancer immune responses.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Breaking News

The Scan

Building Up Numbers

With H3Africa, Charles Rotimi has been working to bolster the representation of African participants and African researchers in genomics, Newsweek reports.

Slow Coverage

NPR reports that government and private insurers are being slow to cover recently approved CAR-T cell therapies.

Many Choices

CNBC reports that there are thousands of genetic tests available for consumers to chose between.

This Week in Nature

In Nature this week: genomic analysis of ducks, whole-genome doubling among tumor samples, and more.

Featured White Papers

Contract Manufacturing in Biotech: Turning Your Supply Chain Into a Competitive Differentiator

Discovering Neuronal Cell Types

Immuno-Oncology: 3 Strategies for Applying Humanized Models

A Guide to Selecting Your Next Immuno-Oncology Model

Jul

24

Featured Webinar

Identifying Inherited Risk Factors of Pancreatic Cancer Using Targeted Sequencing in a Large Cohort

In this webinar, Dr. Fergus Couch from the Mayo Clinic will present data from a large study that used a targeted sequencing panel to determine pancreatic cancer risk associated with inherited mutations in several cancer predisposition genes.

Jul

25

Featured Webinar

Antibiotic Gene Surveillance: What You Don’t See Can Hurt You!

This online seminar will discuss the advantages of incorporating molecular testing into the microbiology laboratory to aid in the identification of relevant antibiotic resistance mechanisms.

Aug

09

Featured Webinar

Analytical Utility of Mass-Spec Liquid Biopsy for NSCLC and Melanoma Samples

In this two-part webinar, Dr. Elin Gray, from Edith Cowan University, and Ms. Weiwei Zhao, from Kingmed diagnostic, will compare the highly sensitive, multiplexed UltraSEEK technology, on the MassARRAY system, to digital droplet PCR (ddPCR) results on melanoma and non-small cell lung carcinoma samples.

Aug

15

Featured Webinar

The Cancer Avatar Project: Analyzing ctDNA to Monitor Treatment Response

This webinar will discuss the Cancer Avatar Project at the California Pacific Medical Center Research Institute (CPMCRI) and the efforts to overcome complexity of tumor profiling using the Accel-Amplicon sequencing workflow from Swift Biosciences.

Main menu